1. IFN-α Is Effective for Treatment of Minimal Residual Disease in Patients with Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: Results of a Registry Study 
Xiao-Dong Mo, Xiao-Hui Zhang, Lan-Ping Xu, Yu Wang, Chen-Hua Yan, Huan Chen, Yu-Hong Chen, Wei Han, Feng-Rong Wang, Jing- Zhi Wang, Kai-Yan Liu, Xiao-Jun Huang 
Biology of Blood and Marrow Transplantation 
Volume 23, Issue 8, Pages (August 2017)
DOI: /j.bbmt
Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

2. Figure 1
Diagram of patients enrolled. MRD-directed DLI was the first choice for patients in MRDco+ group, and those who could not receive DLI because of patient refusal received IFN-α treatment.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

3. Figure 2
Cumulative incidence of (A) NRM (4.3%) and (B) RM (6.8%) at 2 years after MRD-directed IFN-α treatment.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

4. Figure 3
Cumulative incidence of relapse at 2 years after MRD-directed IFN-α treatment and according to (A) MRD status before allo-HSCT (23.2% versus 5.6%, P = .010), (B) MRD status before IFN-α treatment (12.1% versus 11.1%, P = .809), and (C) MRD status after IFN-α treatment (23.1% versus 6.2%, P = .003).
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

5. Figure 4
Probabilities of DFS at 2 years after MRD-directed IFN-α treatment and according to (A) MRD status before allo-HSCT (68.0% versus 89.6%, P = .006), (B) MRD status before IFN-α treatment (81.1% versus 86.5%, P = .726), and (C) MRD status after IFN-α treatment (.0% versus 88.0%, P = .001).
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

6. Figure 5
Probabilities of OS at 2 years after MRD-directed IFN-α treatment and according to (A) MRD status before allo-HSCT (83.9% versus 89.6%, P = .380), (B) MRD status before IFN-α treatment (87.4% versus 87.4%, P = .931), and (C) MRD status after IFN-α treatment (47.2% versus 91.8%, P = .002).
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

7. Figure 6
(A) Relapse, (B) DFS, and (C) OS at 2 years after allo-HSCT in MRD-positive patients who received IFN-α treatment and those who did not receive intervention. Cumulative incidences at 2 years after allo-HSCT with 95% confidence interval are shown.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions